These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27069189)

  • 1. Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Windrichova J; Fuchsova R; Kucera R; Topolcan O; Fiala O; Finek J; Slipkova D; Karlikova M; Svobodova J
    Anticancer Res; 2016 Apr; 36(4):1973-8. PubMed ID: 27069189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
    Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
    Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Assessment of Novel Biomarkers in Bone Metastatic Disease Using Multiplex Measurement and Multivariate Analysis.
    Windrichova J; Kucera R; Fuchsova R; Topolcan O; Fiala O; Svobodova J; Finek J; Slipkova D
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818807466. PubMed ID: 30343636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
    Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
    J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
    Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
    Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
    Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
    Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Windrichova J; Fuchsova R; Kucera R; Topolcan O; Fiala O; Finek J; Slipkova D
    Anticancer Res; 2017 Mar; 37(3):1501-1505. PubMed ID: 28314325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
    Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M
    Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone remodeling markers in the detection of bone metastases in prostate cancer.
    de la Piedra C; Castro-Errecaborde NA; Traba ML; Méndez-Dávila C; García-Moreno C; Rodriguez de Acuña L; Rodriguez-Molina J
    Clin Chim Acta; 2003 May; 331(1-2):45-53. PubMed ID: 12691863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer.
    Lyubimova NV; Pashkov MV; Tyulyandin SA; Gol'dberg VE; Kushlinskii NE
    Bull Exp Biol Med; 2004 Jul; 138(1):77-9. PubMed ID: 15514730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival.
    Johansen JS; Brasso K; Iversen P; Teisner B; Garnero P; Price PA; Christensen IJ
    Clin Cancer Res; 2007 Jun; 13(11):3244-9. PubMed ID: 17545529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TARTRAT-RESISTANT ACID PHOSPHATASE AS BONE'S RESORBTION MARKER IN PATIENTS WITH BONE METASTASES].
    Dedkov AG; Boychuk SI; Stakhovsky EA; Kukushkina MN; Kovalchuk PA
    Lik Sprava; 2015; (5-6):104-9. PubMed ID: 27089726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
    Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY
    Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer.
    Lumachi F; Santeufemia DA; Del Conte A; Mazza F; Tozzoli R; Chiara GB; Basso SM
    Anticancer Res; 2013 Jun; 33(6):2593-6. PubMed ID: 23749913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.